RNA interference market seen reaching $8.57 billion by 2030

The global RNA interference technology market is projected to grow from $4.67 billion in 2025 to $8.57 billion by 2030, according to The Business Research Company. Demand from oncology, gene silencing research and better delivery systems is helping push the sector higher, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - RNA interference technology is moving from a research tool into a bigger role in drug discovery and therapeutic development. - The market growth points to rising demand for targeted gene silencing, personalized medicine and RNA-based treatments, especially in cancer and rare disease research. - The expansion also signals more investment in delivery systems, chemical modifications and functional genomics platforms.

What happened: - The Business Research Company said the global RNA interference technology market was valued at $4.67 billion in 2025 and is expected to reach $5.29 billion in 2026. - The same report forecasts the market will climb to $8.57 billion by 2030. - The report was published Sept. 22, 2026, from London. - A free sample of the report is available here. - The full report is available here.

The details: - The market is expected to grow at a 13.2% compound annual growth rate in 2026. - The report projects a 12.8% CAGR through 2030. - Growth is tied to increased use of gene knockdown methods, improvements in genomic sequencing and stronger funding for molecular biology research. - Early use of siRNA-based experimental therapies is also supporting demand. - Collaboration between academia and industry in gene function research is adding momentum. - The report points to more clinical approvals for RNA-based therapeutics as a future growth driver. - Other drivers include rising demand for targeted gene silencing, progress in in vivo delivery efficiency, broader biotech pipelines for genetic conditions and more investment in RNA interference drug discovery platforms. - Emerging trends include RNA treatments for rare genetic diseases and oncology, lower off-target effects, improved siRNA stability through chemical modification and wider use of lipid-based and non-viral delivery systems. - The report also highlights growing use of RNA interference in functional genomics and high-throughput validation. - RNA interference is a natural process that silences specific messenger RNA molecules to control protein production. - The technology is used in molecular biology research, drug discovery and therapeutic development. - In oncology, RNA interference can silence cancer-related genes tied to tumor growth, spread and drug resistance. - The National Cancer Institute projected about 2,041,910 new cancer diagnoses and 618,120 deaths in the U.S. in May 2025, underscoring the need for new cancer therapies. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report update adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The report suggests RNA interference is benefiting from a broader shift toward precision medicine and more selective therapies. - The emphasis on delivery systems and off-target reduction shows the market is still working through technical barriers to wider clinical use. - North America’s lead reflects its research base and biotech funding, while Asia-Pacific’s growth points to expanding investment and healthcare demand.

What's next: - More RNA-based therapeutic approvals could accelerate commercial growth. - Improved delivery methods and chemical stabilization may expand real-world use beyond research settings. - Oncology and rare disease pipelines are likely to remain the main areas to watch as the market scales.